Summary of Key Points • Lung cancer is increasingly understood at the molecular level; N-of-1 trials are becoming more relevant with the use of biomarker assessment and targeted therapies. •…

Summary of Key Points • Despite two decades of progress, the prognosis for patients with lung cancer remains poor. Therefore forming new hypotheses and conducting clinical trials to investigate this…

Summary of Key Points † Deceased. • To describe the functions of advocacy. • To describe how lung cancer advocacy groups accomplish their goals. • To describe how they can…

Summary of Key Points • Surgery remains the most effective curative approach for early-stage (IA–IIB) NSCLC. Selected cases with clinical stage IIIA disease equally benefit from radical resection. • Stereotactic…

Summary of Key Points • Epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), BRAF, C-ros oncogene 1 (ROS1), ret proto-oncogene (RET) tyrosine kinase inhibitors (TKIs), several antiangiogenesis agents, and…

Summary of Key Points • Performance status is universally recognized as an independent prognostic factor and typically correlates with the extent of tumor burden. • As first-line therapy, platinum agent…

Summary of Key Points • Immunotherapy has entered a new era in lung cancer and is rapidly changing the standard of care. • Vaccines as monotherapies have shown marginal efficacy…

Summary of Key Points • Treatment of lung cancer is rapidly evolving. Large cell carcinomas as a group have therapeutically relevant driver mutations in nearly 40% of cases. • Despite…

Summary of Key Points • Discussed are tumor factors that affect treatment responses and outcome and host genetic elements that affect drug metabolism. Only pharmacogenomics elements that interact with chemotherapeutic…